Skip to main content

Peer Review reports

From: Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer

Original Submission
23 Mar 2011 Submitted Original manuscript
29 Mar 2011 Author responded Author comments - Martin Schlumberger
Resubmission - Version 2
29 Mar 2011 Submitted Manuscript version 2
9 Aug 2011 Author responded Author comments - Martin Schlumberger
24 Jul 2011 Reviewed Reviewer Report - Dirk Vordermark
Resubmission - Version 3
9 Aug 2011 Submitted Manuscript version 3
Publishing
11 Aug 2011 Editorially accepted
11 Aug 2011 Article published 10.1186/1471-2407-11-349

You can find further information about peer review here.

Back to article page